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ABSTRACT 
In society, breast cancer is erroneously considered to be a female disease. Information regarding 
the psychosocial, sociocultural, and familial experiences of men diagnosed with breast cancer 
remains scant. Given the low incidence of male breast cancer in the general population, all 
diagnosis are considered as an indication for referral for genetic counseling and /or testing. Thus, 
counselors are often involved in the care of men with breast cancer and assist patients in 
understanding and adapting to the medical and psychosocial implications of genetic 
contributions to disease.   Genetic counselors are in a position to inform not only men with breast 
cancer, but also all at risk family members of the implication of genetic risk information. 
Because of the broad reach of counselors to many individuals, which makes it relevant to public 
health, it is important to get a baseline picture of the current state of the counseling environment 
so that potential issues can be identified that might inadvertently perpetuate the stereotypes 
surrounding these men. It is also important for counselors to be aware of their own beliefs about 
the process of counseling men with breast cancer as such beliefs can influence assumptions made 
about the counselee and therefore can potentially affect the dynamics of the counseling session. 
We conducted a survey study of genetic counselors in the United States to assess these issues. 
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 The majority of respondents are female with 1-5 years’ experiences in cancer genetic 
counseling and reported seeing an average of 1-5 males breast cancer patient per year. The 
genetic counseling environment appears to be supportive for men with breast cancer. Gender 
does not play a role in the comfort level of either the counselor or counselee. Men appear to pay 
a more active role in the genetic counseling process than the literature suggests.  This may be due 
to the fact that counselors consider themselves to be an important source of support for these 
men and often take a proactive approach in the assessment of psychosocial needs. In conclusion, 
more research is needed to determine specific informational and psychosocial needs of men with 
breast cancer so that counselors can tailor a session which will assist men to make optimal health 
care choices. 
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1.0  INTRODUCTION 
This descriptive study was undertaken to supplement the current literature regarding the genetic 
counseling of men diagnosed with breast cancer. Genetic counselors are in a position to both 
inform men with breast cancer of their genetic risks and to help them explore personal health 
care options. Genetic counselors are also in the position to inform at-risk family members of the 
implications of genetic risk information concerning a diagnosis of breast cancer in males within a 
given family by directly counseling those affected or by assisting the individual to relay cancer 
risk to their families. Because of the broad reach to many individuals, it is particularly important 
that the genetic counseling environment be supportive of the unique issues surrounding men who 
are diagnosed with breast cancer. It is important to get a baseline picture of the current state of 
the genetic counseling environment so that we can identify any issues that may adversely affect 
the relationship between the counselor and the man. These issues, as proposed by the literature, 
include both a lack of dedicated support systems and dedicated research for men with breast 
cancer, and a sense that breast cancer is a gendered disease. New research ideas into the male 
experience of breast cancer may also be generated   It is also important for counselors to be 
aware of their own beliefs concerning counseling men with breast cancer to avoid any 
disruptions in the working relationship which can result when a counselor’s beliefs influence the 
assumptions made concerning a counselee. For the purposes of this research, the environment is 
defined as the physical environment in which genetic counseling takes place (i.e. office. 
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counseling room, conference room, etc.) and the values and beliefs of genetic counselors 
concerning the sociocultural, psychosocial, and familial influences that men with breast cancer 
experience in society.  
1.1 SPECIFIC AIMS 
Aim 1 To provide a description of the genetic counseling environment that men diagnosed 
with breast cancer experience in the United States. 
Aim 2 to provide genetic counselors with an opportunity to increase self- awareness about 
counseling men with breast cancer. 
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2.0  BACKGROUND 
Male breast cancer (MBC) is a rare disease. It occurs when malignant cells form in the tissues of 
the breast. MBC is uncommon because male breasts have ducts that are less developed and are 
not exposed to growth - promoting female hormones; however, any man can still develop breast 
cancer. Like most cancers, MBC is a disease of aging. Age frequency distribution for males is 
unimodal with peak incidence in the late sixth and early seventh decade (Contractor 2008 ). The 
mean age of diagnosis for men is 67 years (Giordano 2005). There are factors other than age that 
can increase the risk for breast cancer in men such as excessive alcohol consumption, radiation 
exposure, certain diseases, obesity and genetic factors. The typical presentation of MBC in 75-
95% of men is a hard non-tender mass with a predilection for the left side in a ratio of 1.07-1 
(Contractor 2008). Nipple involvement manifesting itself as retraction, nipple discharge, fixation, 
or eczema occurs in 40-50% of patients (Contractor 2008).  The cancer is often initially detected 
by the man himself.  Mammography, ultrasound tests and cytology tests if nipple discharge is 
present may be utilized in the process of detection. A biopsy is used to make a definite diagnosis 
of breast cancer which will include the type and stage.  Knowledge of the etiology, pathology, 
and clinical management of male breast cancer is not as well understood as that of female breast 
cancer. There is a need to better understand this disease. Because of its rare nature, large 
randomized trials have not been done and are not practical. Consequently, most of the available 
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information has been based on small, individual retrospective studies and extrapolation from 
female studies.  
2.1 PATHOPHYSIOLOGY 
All of the histological variants of breast cancer have been seen in men. Infiltrating ductal 
carcinoma is the most predominant subtype in men with an incidence ranging from 64-93% 
(Contractor 2008). The second most common type is papillary which is seen in 2.6-5% of all 
male breast cancer cases followed by medullary, tubular, small cell and mucinous carcinomas 
which together constitute less than 15% of cases (Contractor 2008). Lobular cancer is extremely 
rare in males. This is logical as the male breast tissues lacks terminal lobules unless exposed to 
exogenous estrogen. Estrogen appears to have a role in the development of breast cancer in men 
as it does in women; therefore, a discussion of the sources of estrogen in men under normal 
conditions is appropriate and might help to understand how some diseases and environmental 
exposures can increase the risk of breast cancer in men.  
Sources of endogenous estrogen in men can be classified into gonadal and extragonadal. 
The testes produce only 15% of the circulating estrogen in the body (Pant 2007). Extragonadal 
sources of estrogen production include the mesenchymal cells of the adipose tissue or skin, 
osteoblasts in the bone, vascular endothelial and aortic smooth muscle cells, medial 
preoptic/anterior/basal hypothalamus, and the amygdale (Pant 2007). The third source of 
estrogen in males arises from the aromatization of the androgen testosterone which is dependent 
upon the enzyme aromatase encoded by the CYP19 gene. This conversion takes place in 
peripheral adipose tissue. In addition to testosterone, androstenedione can also be converted to 
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estrogen specifically estrone.  Since men have less adipose tissue in the breast, the local estrogen 
production is much lower than that for women which might be one of the reasons for the lower 
breast cancer rates in men as compared to women.  
Molecular markers are important in the study of breast cancer in that they can give 
information as to what therapeutic strategy to utilize in caring for the patient.  These markers can 
also provide clues as to the prognosis of the patient. Several molecular markers have been 
studied and identified in male breast cancer some of which include the estrogen receptor, 
progesterone receptor, Human Epidermal Growth Factor Receptor-2, androgen receptor, P 53 
gene, and MLB-1 index.  Approximately 64 to 85% of breast cancers in men are estrogen 
receptor positive and more than 70% are progesterone receptor positive. Such high levels of 
positivity may be due to low estrogen levels leaving receptors available for binding (Contractor 
2008).  Androgen receptor status varies in the literature from negative to 95% and it is not well 
understood in terms of its role in pathology and survival of breast cancer in men (Contractor 
2008).  P 53 gene is a tumor suppressor gene that regulates cell growth by inducing blockage in 
the cell cycle. Its overexpression has been correlated with recurrence and poorer prognosis in 
some patients, whereas no such correlation has been found in others. It remains unknown as to 
how overexpression of this gene contributes to the prognosis of breast cancer cases in men.  
Human Epidermal Growth Factor-2 or Her2neu is a proto-oncogene that codes for a tyrosine 
kinase transmembrane receptor. Her2Neu is rarely overexpressed in MBC. Increased 
gelatinolytic activity of the enzymes MMP-2 and MMP-9 is related to an increased tendency for 
metastasis and poor prognosis. Tumor expression of the proliferation marker MIB-1 and the cell 
cycle protein p27 have been shown to be good predictors of lymph node metastasis in MBC. 
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2.2 EPIDEMIOLOGY 
The lifetime risk of breast cancer in men has been estimated at about 1 in 1000 (NCCN 
2013).The American Cancer Society estimates that about 2,240 new cases of invasive cancer will 
be diagnosed among men in 2013 (ACS 2013). The American Cancer Society estimates that 
approximately 410 men will die from breast cancer in 2013 (ACS 2013). Little is known about 
the etiology of male breast cancer. The rare nature of male breast cancer limits the application of 
epidemiologic methods making it difficult to establish associations between potential risk factors 
and disease occurrence. In addition, breast tumors in men are often small which limits the 
amount of tissue available for research after the requisite pathology and molecular studies. 
Nevertheless, there exists evidence in the literature for both genetic and epidemiologic risk 
factors for MBC.  
Any environmental factor or disease that increases the level of circulating estrogen 
increases the risk of breast cancer in men. There are some known risk factors and some risk 
factors that have merely been implicated in the risk of breast cancer in men.  Obesity is a known 
risk factor that leads to higher levels of estrogen due to large amounts of adipose tissue that 
facilitates the conversion of steroid androgens to estradiol and estrone. Trans-sexuality is factor 
that has been implicated in the etiology of male breast cancer in that the treatment often includes 
both prolonged female hormone exposure to stimulate development of a female breast and 
surgical castration which together creates a high estrogen to androgen ratio by lowering 
androgen levels.  Prostate cancer whose treatment can also expose men to high levels of estrogen 
might be a risk factor. Another possible risk factor is liver cirrhosis that produces excessive 
levels of estrogen and a reduction in free testosterone due to an elevation of sex binding steroids. 
Testicular disorders such as undescended testes, mumps orchitis, congenital inguinal hernia and 
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testicular injury are known to increase the risk of breast cancer in men.  These disorders are 
associated with low levels of androgens which have consistently been associated with an 
increased risk of breast cancer. Gynecomastia may be associated with breast cancer in men, but 
this association remains unclear in healthy men who exhibit gynecomastia.   Gynecomastia may 
occur both with exposure to estrogen and certain classes of non-hormonal drugs such as digitalis, 
cimetidine, reserpine, thiazide, and tricyclic antidepressants (Weiss 2005). Gynecomastia is seen 
in men over 50 as a consequence of the natural decline in testosterone levels accompanied by 
constant level of estradiol which results in an estradiol testosterone imbalance. Gynecomastia 
can also be present in healthy young men.   
There is some evidence that electromagnetic field exposure may be a risk factor for breast 
cancer in men.  It has been hypothesized that electromagnetic field exposure may affect the 
pineal gland leading to decreased levels of melatonin. There is in vitro evidence that melatonin 
blocks estrogen-induced proliferation of human breast cancer cells. High temperature is a 
suggested risk factor in that heat leads to testicular damage, consequently altering levels of 
circulating estrogen and androgen. Radiation exposure is considered to be a known risk factor for 
breast cancer in men.  Some examples of radiation exposure are chest fluoroscopy and repeated 
chest x-rays. Though studies are few in number, there is evidence that polycyclic aromatic 
hydrocarbons or PAH may be a risk factor for breast cancer in men. An increase in risk has been 
found in workers exposed to PAH as opposed to those not exposed in some studies. These results 
can be considered to be inconsistent as some studies have not found such as association. 
In general, there is little evidence to suggest dietary factors such as meat consumption 
and alcohol play a role in the development of breast cancer. Evidence for a protective effect of 
fruits and vegetables remains inconsistent (Weiss 2005). 
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2.2.1 Genetics 
There are both chromosomal and molecular genetic factors that can lead to an increased risk for 
breast cancer in men. Klinefelter syndrome is defined by the karyotype 47XXY and occurs in 
approximately 1 n 1000 men (Weiss 2005). It is usually not recognized until after puberty. 
Patients exhibit a eunuchoid habitus, gynecomastia, small and firm testes, low testosterone 
concentrations, and increased secretions of follicular secreting hormone. A high estrogen to 
androgen ratio exists. When compared with the frequency of the disorder in the general 
population, it seems that breast cancer might be at least 20 times more common in males with 
Klinefelter syndrome compared with males without this condition (Weiss 2005). Some possible 
explanations for this increased risk include abnormal hormonal stimulation of cell proliferation 
in mammary ductal epithelium and treatment with exogenous testosterone which is converted to 
estrogens in peripheral adipose tissues.   
At the molecular level, the tumor suppressor genes BRCA1 and BRCA2   have been 
found to play an important role in breast cancer in both males and females. The  BRCA1 gene is 
located on chromosome 17q21 and spans 5.6 kilobases of genomic DNA, comprising 1,863 
amino acids; whereas, the BRCA2 gene is located on chromosome 13q12 and codes for 3,418 
amino acids (Peshkin 2005). Both of these genes maintain genomic integrity by encoding nuclear 
proteins that help repair double-stranded DNA breaks which can occur during homologous 
recombination or as a result of DNA damage. Germline mutations in either of these genes can 
predispose an individual to an increased risk of certain types of cancer. These genetic mutations 
are transmitted in an autosomal dominant fashion in affected families.  Offspring of carriers have 
a 50% chance of inheriting the mutation and a 50% chance of not inheriting the mutation.  
Tumor formation in carriers of BRCA1 or BRCA2 germline mutations follows the two- hit 
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hypothesis in that both alleles of BRCA1 and  BRCA2  lose function in tumor cells ( Nussbaum 
2007 ). 
2.2.1.1 Hereditary Breast and Ovarian Cancer Syndrome (HBOC ) 
Hereditary breast and ovarian cancer syndrome is a genetically determined cancer syndrome that 
is caused by mutations in BRCA1 and BRCA2. BRCA gene mutations account for about 50% of 
predisposition to inherited breast cancer (Euhas 2013).   The following criteria are suggestive of 
an HBOC syndrome (NCCN Version 2013):  
o Personal History of breast cancer plus one or more of the following:  
 diagnosed less than or equal to age 45 
 diagnosed at any age with 1 or  more close blood relative (first, second or 
third degree)with breast cancer less than or equal to age 50 and/or 1 or more 
close relative with epithelial ovarian cancer at any age 
 two breast primaries when first breast cancer diagnosis occurred less than or 
equal to age 50 
 diagnosed less than or equal to age 60 with a triple negative breast cancer 
 diagnosed at less than or equal to age 50 with a limited family history such as 
fewer than 2 first or second degree female relatives or female relatives 
surviving beyond 45 years in either lineage 
 diagnosed at any age with two or more close blood relatives with pancreatic 
cancer or aggressive prostate cancer (Gleason score greater than or equal to 7) 
at any age  
 diagnosed at any age with 2 or more close blood relatives with breast cancer at 
any age 
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 close male blood relative with breast cancer 
 ethnicity associated with higher mutation frequency e.g. Ashkenazi Jewish 
ancestry 
 
o Personal history of male breast cancer 
o Known deleterious BRCA1/BRCA2 familial mutation 
o Personal history of pancreatic cancer or aggressive prostate cancer at any age with 
2 or more close blood relatives with breast and /or ovarian and /or pancreatic or 
aggressive prostate cancer (Gleeson score greater or equal to 7) at any age 
o Family history of a first or second degree relative meeting any of the above 
criteria or a third degree blood relative with breast cancer and/or ovarian cancer 
with 2 or more close blood relatives with breast cancer (at least one with breast 
cancer greater than or equal to 50 years) and/or  ovarian cancer 
 
Both BRCA1 and BRCA2 germline mutations confer increased cancer risks for men as 
well as women. Men with mutations in BRCA1 are at increased risk for cancers of the prostate 
and breast. Lifetime breast cancer risk is estimated at 1.8% for men with BRCA1 mutations 
(Euhus 2013).  BRCA2 gene appears to be the more important gene for cancer susceptibility in 
men in that there is a wider spectrum of cancer  risks mainly breast,  prostate, pancreas and 
melanoma of skin and eye (Liede 2004). It is estimated that 4% to 16% of male breast cancers 
are associated with a BRCA2 mutation (Coffy 2013). Friedman et al. analyzed a   population-
based series of 54 male breast cancer cases from the US for mutations in BRCA1 and BRCA2. 
They found that 3% of the male breast cancer cases with no family history carry a BRCA2 
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mutation, whereas 11% of cases with an affected first- degree relative carry a BRCA2 mutation. 
Couch et al. analyzed germline DNA from 50 males with breast cancer unselect4ed for family 
history and 26 individuals from site-specific female breast and breast-ovarian cancer families for 
mutations in BRCA2. They found that BRCA2 mutations account for 14% of male breast cancer, 
all but one of which had a family history of male and/or female breast cancer. The lifetime breast 
cancer risk for males with a BRCA2 mutation has been estimated at 8.3% (Euhas 2013). Male 
BRCA2 germline mutation carriers may also be at risk for stomach cancer, gallbladder cancer 
although reports are very rare and magnitude of risk is poorly defined (Leide 2004).  
BRCA1 and BRCA2 mutations are rare in most populations, occurring in approximately 
1 of 400 individuals, but much more common in Ashkenazi Jewish populations in which 1 of 40 
individuals carries 1 of 3 main disease-causing mutations: 2 in BRCA1 ( 185delAG and5382 
insC) and the 6174delT mutation in BRCA2 (Shannon 2012). There are differences in the 
distributions of certain mutations in varied ethnic populations which suggest a founder effect.  
Other founder mutations have been identified, but the utility of these in the US population is 
minimal (Shannon 2012). 
2.3 DIAGNOSIS AND TREATMENT 
The typical clinical presentation of breast cancer in 75-95% of men is a hard non-tender mass 
with a predilection for the left side in a ratio of 1.07-1 (Contractor 2008). Nipple involvement 
manifesting itself as retraction, nipple discharge, fixation, or eczema occurs in 40-50% of 
patients (Contractor 2008).  Ductal Carcinoma In Situ (DCIS) is rarer in men than women. The 
staging in male breast cancer is similar for female breast cancer and follows the same TNM 
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classification.  Despite the fact that male breast cancer is less aggressive than that found in 
women, axillary node involvement is common. This paradox is believed to be due to lack of 
awareness and delayed diagnosis. 
The small amount of breast tissue in men makes it difficult to perform and interpret 
common diagnostic tools such as ultrasound and mammography. Routine screening is not 
recommended for men due to its low incidence of male breast cancer. Because of the rare nature 
and lack of standardization of imaging strategies, there is less familiarity with the imaging 
features of cancer in the male breast. However, mammography and ultrasound are acceptable 
imaging modalities. Mammography has a sensitivity and specificity for diagnosing MBC of 92% 
and 90%, respectively (Colfry 2013). There are limitations to these techniques as diseases such 
as gynecomastia can mask malignant disease. Also, as male breast cancer usually occurs in the 
subareolar region, evaluations of lesions are made difficult by the shadowing of the nipple.  If a 
lesion is discovered, stereotactic or ultrasound guided biopsy should be used (Colfry 2013). In 
recent years, core needle biopsies or CNB are being used over fine needle aspirations due to the 
idea that CNB provides a more specific or definite diagnosis as well as an assessment of 
prognostic/ predictive factors (Rosa 2010). MRI is increasingly being used in imaging of the 
male breast, mainly for imaging of the contralateral breast following initial diagnosis to establish 
extent of disease prior to surgery.  
The current surgical approach for men with localized breast cancer is the same for 
females with localized breast cancer. Although for many years radical mastectomy was the 
standard of treatment for MBC, modified radical mastectomy or simple mastectomy followed by 
sentinel node biopsy/axillary lymph node dissection has become the standard surgical therapy 
(Colfry 2012). Lumpectomy for men is generally not considered due to the lower volume of 
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breast tissue and more centralized location of the cancer; however, some men with breast cancer 
do have sufficient breast tissues to permit breast conservation.  
Lymph node statuses along with tumor stage are considered to be independent prognostic 
factors for survival in men. Sentinel lymph node biopsy (SNL biopsy)  which predicts status of 
regional  lymph node involvement can be inappropriate as men are often diagnosed at an 
advanced stage. As for those men who are clinically node negative, retrospective studies have 
suggested that axillary staging for these men may be reliable. No prospective studies currently 
exist which demonstrates the sensitivity and specificity of sentinel node biopsy in male breast 
cancer. Despite the limited amount of data, an expert panel convened by the American Society of 
Clinical Oncology concluded that the use of SLN biopsy for men with breast cancer was 
acceptable  (www.uptodate.com).  
An unanswered question is whether MBC has a molecular profile similar to that of 
estrogen-positive breast cancer in women or whether men develop a unique subtype of estrogen- 
positive breast cancer. Another factor that complicates this issue is that we cannot assume the 
hormonal milieu of men is the same as that of postmenopausal women.  Hormonal therapy can 
be divided into two functions. The first function is blocking, downgrading or destroying the ER 
receptor, while the second is to inhibit any mechanism involving estrogen production and 
release. Tamoxifen is the gold standard for treatment of ER positive metastatic breast cancer in 
men. The use of Tamoxifen avoids the surgical morbidity associated with such procedures as 
orchiectomy, adrenalectomy, and hypophysectomy which all have been used in the past to 
decrease the estrogen levels in men with metastatic breast cancer.  Normally estrogen binding to 
a receptor facilitates translation. Tamoxifen is a non-steroidal anti-estrogen that binds the 
estrogen receptor in tumor cells and could initiate the death of the cell or an end to cell 
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replication. The side effects include hot flashes, weight gain, deep vein thrombosis, decrease in 
libido, and sexual dysfunction.  The 5 year duration is extrapolated from studies using female 
breast cancer patients.  Fulvestrant used in the treatment of MBC, albeit rarely. This drug binds 
equally to both types of ER receptors, thereby destroying the receptor. It has a long elimination 
half-life so a monthly dose will be sufficient to maintain a therapeutic plasma concentration. Side 
effects involve the GI tract and vasodilation which are considered to be tolerable. Due to the lack 
of information, the role of Fluvestrant in MBC treatment remains unclear (Sousa 2013). Another 
class of drugs used as part of hormonal therapy is aromatase inhibitors such as anastrozol, 
letrozol and exemestane. This action is reversible i.e. when use is discontinued estrogen levels 
return to normal. Aromatase inhibitors specifically decrease estrogen and do not affect the 
synthesis of other steroid hormones. In the clinical setting, aromatase inhibitors have been used 
to treat some patients with metastatic disease progressing to Tamoxifen and chemotherapy, but 
only small case series are available (Sousa 2013). It is believed that the target male population 
should be 65 years of age or older as there is less free testosterone available for conversion. 
Aromatase inhibitors are unable to inhibit the testicular production of estrogen that is regulated 
by both the Luteinizing hormone (LH) which is sensitive to the feedback effects of testosterone 
and the follicle stimulating hormone (FSH) which appears to stimulate the aromatization of 
androgens to estrogen in Sertoli cells.  Also, the suppression of estrogen from this class of drugs 
can cause an increase of LH and FSH, resulting in a paradoxical increase in substrate for 
aromatase conversion.  Therefore, monotherapy with aromatase inhibitors alone may not be 
optimal. In the clinical setting, aromatase inhibitors have been used to treat some patients with 
metastatic disease progressing toe Tamoxifen and chemotherapy, but only small case series are 
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available (Sousa 2013). There remains insufficient data to support the use or aromatase inhibitors 
as routine hormonal therapy for MBC.  
The role of adjuvant therapy in male breast cancer has not been well established. The 
general consensus gleaned from small retrospective studies and anecdotal observation is that 
adjuvant chemotherapy should be used with node-positive disease. It is also currently accepted 
that chemotherapy can provide palliation in patients with early to advanced disease, patients who 
have not done well with hormonal manipulation, or in those who have hormone receptor 
negative tumors. An optimal chemotherapy regime for men has not been defined.  
Case and population data from the National Cancer Institute’s Surveillance Epidemiology 
and End Result or SEER program for breast cancer diagnosed between 1973 and 2005 was 
studied in an attempt to compare and contrast both male and female breast cancer 
(Anderson2010).  This was one of the largest comparative studies of male versus female breast 
cancer and is considered to be an important source of information in the absence of randomized 
clinical trials for men. A major strength was the supplementation of standard descriptive 
epidemiology with age-period- cohort models adjusted for period and cohort effects and survival 
analysis adjusted for age, stage and grade. (Anderson 2010). Period effects are associated with 
such thing as changing treatment or screening patterns and cohort or generational effects are 
associated with such thing as lifestyle changes or risk factors.  Both period and cohort effects can 
vary between men and women.  In general, breast cancer develops at a later age in men than 
women. Early onset breast cancer are generally female specific (pre menopause) and somewhat 
uncommon in men (Anderson 2010). Anderson et al. defines early onset for men as that 
occurring before age 67. As with women, early onset breast cancer in men most likely has a 
genetic component, i.e. Klinefelter and BRCA mutations.   The results revealed age- specific 
20 
incidence patterns which suggested that the biology of male breast cancer resembled that of late 
–onset (post menopause) and ER positive female breast cancer. The similarity of both age- 
standardized and age-specific incidence trends over time suggest that there are environmental 
and/or other nonhormonal risk factors for breast cancer, such as diet .and obesity  to name a few, 
that are common to  both men and women  (Anderson 2010). Both men and women with breast 
cancer were found to have improved mortality and survival rate over time; however, progress for 
men lags behind that of females. Declining female mortality rates are attributed to adjuvant 
therapy, screening mammography and reduction in hormone replacement therapy. By contrast, 
any decline in male mortality rate is likely a reflection of adjuvant therapy alone as the other two 
factors are not common to the male experience.  The smaller improvement in mortality for men 
versus women might be a reflection of the underutilization of adjuvant therapy specifically 
Tamoxifen in men or non-compliance on the part of the man due to adverse side effects of 
certain treatments.  
2.4 PSYCHOSOCIAL EXPERIENCES 
There is scant information on the psychosocial effects of breast cancer in men as opposed to 
female breast cancer which is considered to be the most studied malignancy in terms of 
psychological effects (Donovan 2007). Men with breast cancer have a unique experience in 
society in that they have a disease considered by society to be female. The issue of gender 
permeates all aspects of the male experience from diagnosis to treatment. Men who are 
diagnosed with breast cancer report feelings of shame and confusion. An exploration of the lived 
experience of men with breast cancer in the United Kingdom found that men viewed a diagnosis 
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of breast cancer as an intrinsic defect which can lead to questions about sexual orientation and 
masculinity (Donovan 2007). A mastectomy is considered to be a significant alteration in male 
self- image, thereby having the potential to impact male sexuality. Mastectomy scars are 
concerning to men in that they feel that it will be seen by society as a mark of femininity. In 
reporting survivor stories by men with breast cancer, the media tends to stress their masculinity 
by referring to  these men as  “ regular” or “normal” men which paradoxically can reflect the 
view that breast cancer is gendered (Donovan 2007). In society, masculinity is often affirmed 
through sexual function. The treatment of male breast cancer can also exacerbate the gendered 
views of breast cancer in that the treatment can interfere with male sexual function.   
Men with breast cancer have reported that health professionals are unaware of the 
specific psychosocial and informational needs of men with breast cancer.  A study which focused 
on the gender differences in psychosocial adjustment to a diagnosis of cancer found that the 
support of health professionals contributed more to the adjustment of men whereas the support of 
family contributed more to the adjustment of women (Fife 1994). A possible reason for this may 
be related to the fact that mend tend to associated illness  with weakness, thereby making it 
difficult for men to solicit support from their family for fear that this may be seen as a flaw in 
masculinity. This can also be a reflection of a man’s tendency to have a task oriented approach to 
problem solving. The support from health professionals can be seen as a component of a working 
relationship with these professionals to solve problems. Avoidance and denial are defense 
mechanisms often used by these men who tend to present to the health care system at a more 
advanced stage than their female counterparts. One explanation might be that the use of the 
health care system does not fit into the concept of masculinity. Also, a period of concealment 
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might be necessary for the man to assimilate all of the unique issues surrounding the fact that he 
is diagnosed with a gendered illness.   
2.4.1 Genetic counseling 
As defined by the American Society of Human Genetics in 1975, Genetic counseling is a 
communication process which deals with the occurrence or risk of occurrence of a genetic 
disorder in a family (Baker et al. 1998). A definition of genetic counseling as per the National 
Society of Genetic Counselors follows:  
o Genetic counselors are health professionals who help people understand and adapt 
to the medical and psychological implications of genetic contributions to disease. 
Genetic counselors interpret family and medical histories to assess the chance of 
disease occurrence. They also educate individuals about such areas as inheritance, 
testing, management, prevention, resources, and research. In addition, genetic 
counselors counsel patient so that they are able   to make informed decisions about 
their personal health care and to also adapt to the risk or condition\ 
 
The American Society of Clinical Oncology recommends that genetic testing be offered 
when 1) the individual has personal or family history features suggestive of a genetic cancer 
susceptibility condition, 2) the test can be adequately interpreted, and 3) the results will aid in the 
diagnosis of influence the medical or surgical management of the patient or family members at 
hereditary risk of a cancer mutation. The selection of appropriate candidates for genetic testing is 
based on the personal and familial characteristics that determine the individual’s prior probability 
of being a mutation carrier, and on the psychosocial degree of readiness of the person to receive 
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genetic test results (NCCN 2013). In population-based series of men with breast cancer 
unselected for family history, 0 to 4% have BRCA1 mutations, while between 5 and 15% have 
BRCA2 mutations, depending on ethnicity and the strength of the family history ; therefore, all 
men with breast cancer are candidates for genetic counseling and BRCA testing 
(www.uptodate.com 2013).  Germline genetic testing is performed on DNA isolated form 
leukocytes obtained from a venous blood sample of from oral epithelial cells obtained from a 
salvia sample (Euhus 2013).  Blood samples would be contraindicated in those who have had 
allogeneic hematopoietic stem cell transplantation. In such cases, DNA of the individual being 
tested should be extracted from a fibroblast culture.  If this is not possible, buccal cells may be 
considered; however, genetic testing using buccal cells may be limited in this population as 
buccal epithelia cells may be replaced by donor-derived cells over time.  When testing is 
indicated, BRCA1 and BRCA2 mutations are identified through either targeted mutation analysis 
or sequence analysis in combination with deletion/duplication analysis. Targeted mutations 
analysis is useful when searching for known specific genetic mutations suspected to be present 
from prior family testing or because the population at risk is known to possess certain mutations 
at higher frequencies, such as 187delAG, and 5385insC in BRCA1 and 6174delT in BRCA2 in 
patients of Ashkenazi Jewish heritage (Gage 2012). Full sequencing plus deletion/duplication 
analysis is recommended when the suspected mutation in BRCA1 or BRCA2 in a given family is 
previously unidentified. Mutation detection frequency was > 88% when comprehensive analysis 
was done on individuals with families with demonstrated linkage to BRC1 or BRCA2 (Gage 
2012). NCCN currently recommends for all individuals undergoing BRCA analysis a test called 
the BRCAnalysis Large Rearrangement Test or BART which provides a more comprehensive 
analysis test for large rearrangements in BRCA1 and BRCA2. These large rearrangements 
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account for up to 17% of deleterious BRCA gene mutations in individuals of Near-East/Middle 
East ancestry and up to 22 % for individuals with Latin American /Caribbean ancestry (Euhus 
2013).   
2.4.1.1 Possible Genetic testing outcomes 
Genetic counseling is highly recommended by a qualified health professional  with expertise and 
experience in cancer genetics such as a genetic counselor, medical geneticist, oncologist surgeon 
or oncology nurse during the process of genetic testing and after the result are disclosed (NCCN 
2013).   The possible testing outcomes are 1) positive for familial mutation and 2) negative for 
familial mutation  3) variant of unknown clinical significance (NCCN 2013).  
In those affected probands with no known familial BRCA1/BRCA2 mutation, 
comprehensive genetic testing, which includes full sequencing of BRCA1/BRCA2 and testing 
for large genomic rearrangements, may be offered (NCCN 2013).  If the proband is unaffected, 
testing of family members with highest likelihood of a BRCA1BRCA2 mutation should be 
performed (NCCN 2013). If more than one family member is affected, first consider: youngest 
age at diagnosis, bilateral disease, multiple primaries, ovarian cancer and most closely related to 
the proband (NCCN 2013). If no living family member with breast or ovarian cancer, consider 
testing first- or second-degree family members affected with cancers thought to be related to 
BRCA1/BRCA2 such as prostate, melanoma, pancreas (NCCN 2013).  In those individuals with 
a known familial mutation, it is recommended that BRCA1/BRCA2 testing for the specific 
familial mutation be offered (NCCN 2013). 
Even if no mutation is identified, it is possible that the cancer in the proband is due to 
another gene that may or may not yet be identified.  Testing for other hereditary breast syndrome 
should be considered.  The decision to test other genes should be guided by both paternal and 
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maternal family history and phenotypic clues. Also, current available gene tests are not capable 
of identifying every deleterious mutation. The sensitivity of BRCA gene testing is estimated at 
80% to 90% (Euhus 2013). Attempts to contact patients with these noninfomative negative gene 
tests to offer retesting should be done as new technology becomes available.  If a noninfomative 
test result cannot be resolved, then recommendations for medical management should be based 
on the individual’s personal and family history of breast cancer.  
Another uninformative result is the variant of unknown significance or VUS.  For 
BRCA1 and BRCA2, it is estimated that in the Caucasian population 2.9% of identified 
mutations fall into this category (Euhus 2013). Work is continually ongoing to definitively 
classify these variants as deleterious or nondeleterious. A record of the genetic test result and 
patient contact information needs to be maintained so that these individuals can be contacted 
when the VUS is classified as deleterious or nondeleterious (Euhus 2013).  Testing family 
members for the VUS should not be used for clinical purposes. Referrals to research protocols 
can be considered. As with the other type of noninfomative test result, medical management 
should be based on the individual’s personal and family history of breast cancer.  
For both affected and unaffected individuals of Ashkenazi Jewish decent with no known 
familial mutation, first test for the three most common mutations (NCCN 2013).Then, if negative 
for the three mutations and ancestry also includes non-Ashkenazi Jewish relatives or other 
HBOC criteria is met, consider comprehensive genetic testing, 
2.4.1.2 Medical management for positive test results 
The recommendations for those men found to have a deleterious BRCA mutation are as follows 
(NCCN 2013): 
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o Breast self-exam training and education starting at age 35.  
o Clinical breast exam, every 6 – 12 months, starting at age 35.  
o Consider baseline mammograms at age 40; annual mammograms if gynecomastia 
or parenchymal/ glandular breast density on baseline study. 
o Adhere to screening guidelines for prostate cancer – baseline digital rectal 
examination and PSA at age 40.  
2.4.1.3 Psychosocial issues relating specifically to genetic counseling 
Some factors in the literature associated with greater uptake of genetic testing include the 
following: women from multi-case families, higher economic status, higher levels of education 
and higher self-perceived risks of cancer (Daly 2009). Reasons for undergoing testing for 
BRCA1/2 include: surgical decision making, gaining information to guide screening and 
preventive practices, obtaining information for family members and peace of mind (Daly 2009). 
Despite the fact that the information is sparse, there are some unique themes emerging 
from the research about the experiences of men with breast cancer and genetic testing.  Fewer 
men than women come forward for predictive BRCA1/2 testing and men who do proceed with 
genetic testing have a tendency to miss appointments, drop out of testing protocols and 
experience difficulties establishing  appropriate posttest care (Lobb 2009). There is limited data 
that suggests that men who do pursue testing may be acting under pressure exerted by family 
members and not necessarily for their own benefit (Daly 2009). Also, there is evidence in the 
literature that just knowing their mutation status is not sufficient motivation for a man to pursue 
genetic testing (Lobb 2009). Concern for their offspring plays a role in the decision to pursue 
genetic testing: men tend to view the decision to pursue testing out of concern for their family 
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rather than as a benefit to themselves. Men feel that they have a responsibility to get testing not 
only for optimal health practices for themselves, but also so that their children can make 
informed health care choices. Men can experience a conflict between the sense of duty to warn 
their children and the sense of duty to protect them.  
Women are emerging as strong influential figures for men in the total process of genetic 
counseling from decision making to communication of risk information to family members.  
Women have been found to be the initiators of genetic testing of the male. This  can be a 
reflection of the fact the women often play the main role in both providing health care and 
communicating  with health care systems on behalf of their husband and children. (Strosvik 
2009). It can also be a reflection of the different support systems that men and women have 
which can influence the number of people considered to be a confidant. Men regard their wives 
or significant other as their closest personal contact and support system compared with women 
who tend to have a broader support system which may include other women and health 
professionals as well as their husband/partner. Also, health practices have been found to differ 
between men and women. Women express a higher perception of health risk and vulnerability to 
health hazards than men, resulting in more proactive health care practices which may include 
genetic testing.  Social stereotypes of masculinity equate illness with personal weakness and may 
result in an avoidance of the health care system by the male. Men’s health behaviors are 
influenced by the social context in which they live. In other words, a male’s perception of male 
behavior forms his own behavior in terms of health care practices. Women might play a role in 
the formation of male health care practices in two different ways.  Men’s fear of being perceived 
as feminine leads them to define themselves in opposition to woman (Mahalik 2007). If a man 
constructs his identity in contrast to women, he may do the opposite of what he perceives as 
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normative for this group (Mahalik 2007). Alternatively, men may view women as a salient 
reference group because they also provide important information about health behavior (Mahalik 
2007). 
There is evidence that men may be more willing to take a more active role in the process 
of genetic testing. A pilot study conducted by Juan et al. in 2008 showed evidence that men may 
be more willing to take a more active role in the genetic testing process. Juan et al. developed an 
aid to help men with a strong family history of breast and/or ovarian cancer in decision making 
with regards to genetic testing. The aid included background information on BRCA genes, a 
description of the testing process and possible test results, and a discussion of the impact of 
testing on the man and his children. All of the men in the study would recommend the aid to 
others and 96% reported that they were satisfied with the aid (Juan 2008). Despite the avoidance 
denial coping mechanism found upon the diagnosis of breast cancer described in the literature, 
men do report a strong sense of duty to inform other family members of the genetic testing 
results. Men have reported both a need to be informed as to which family members need to be 
aware of testing results and a need to learn how to better communicate genetic risk to these 
family members. Still within the family, women often take on the role of the disseminator of risk 
information, even for those family members of their partner whom they do not know well.  From 
the limited body of research, men are also less likely to be included in family conversations 
about familial cancer risk and less likely to be informed of test results received by their female 
relatives (Daly 2009).  
Genetic testing may affect family dynamics through the identification of at-risk relatives 
who may adopt their carrier status as a component of their identity.  For both carriers and non- 
carriers, genetic information becomes a component of their sense of self and family. A study of 
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at risk male responses to BRCA1/2 testing was undertaken by conducting interviews with at risk 
men by Hallowell et al. in 2006. The study population was men over the age of 18 with no 
previous diagnosis of cancer or mental illness who had previously received a BRCA testing 
result. They conducted interviews with 5 BRCA positive males and 12 males who were found 
not to have a BRCA mutation (Hallowell 2006). BRCA negative men were found to willingly 
accept responsibility for disrupting the family dynamics in the period in which the test results 
were unknown. In other words, they accepted responsibility for the fact that their offspring 
remained at risk while the results of the testing remained unknown. This is theorized to be a way 
of both reaffirming not only their obligation to the family as a responsible parent, but also their 
role in fixing any breaks in family dynamics that have occurred during the testing process  
(Hallowell 2006).  In addition, BRCA negative men stated that they would have taken 
responsibility for the transmission of increased risk had they tested positive. This could be 
another example of a man strengthening his position in the family as a responsible parent. 
Among the BRCA negative men, there was relief for their children, but also evidence of 
survivor’s guilt. Some of the men expressed the sentiment that it would have been better for 
them to have a mutation rather than their female sibling as the risk of cancer is lower for men.  
BRCA positive men in this study felt the transmission of the gene was a chance event over which 
they had no control. This view is such that it exonerates them from blame and in a sense helps 
them to come to terms with putting their children at risk. Both examples can be viewed as 
evidence that both BRCA negative and BRCA positive  males attempt to reconcile their genetic 
makeup with their sense of self and family and all the responsibilities that come with being a 
member of a family.  
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2.4.2 Transference and Countertransference 
Transference and countertransference are present in a variety of relationships including genetic 
counseling. Transference is defined as an unconscious transference of experiences from one 
interpersonal relationship to another (Jones 2004). Thoughts and feelings about past situations 
are projected onto current relationships. Transference serves as a means for alleviating anxiety 
by preserving the past and has the potential to prevent self-development. Countertransference is a 
response to transference that can complicate the working relationship. Two types have been 
found in genetic counseling. Associative countertransference arises when a patient shares an 
experience that brings the counselor back in time to her memories of a similar experience (Baker 
1998). The second type of countertransference is called projection in which a counselor makes 
an assumption about the experiences of a counselee based on his or her own past experiences 
(Baker 1998). As professionals, genetic counselors have a responsibility to identify any process 
which can affect the genetic counseling process. We must be aware of our vulnerabilities, 
countertransference triggers and abilities to take in the experiences of the counselee (Baker 
1998).  This self-awareness can be achieved through discussions with colleagues, case 
discussions in which psychological issues are considered and sometimes therapy (Baker 1998).  
2.5 SOURCES OF PATIENT SUPPORT 
AND RESOURCES 
The following are some resources for men with breast cancer: 
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o American Cancer Society. Breast Cancer in Men: Detailed Guide 
www.cancer.org/Cancer/BreastCancerinMen/DetailedGuide/index 
o John W. Nick Foundation 
       www.malebreastcancer.org 
o Mayo Clinic. Male Breast Cancer 
       www.mayoclinic.com/health/male-breast-cancer/DS00661 
o Menstuff, The National Men’s Resource. Breast Cancer in Men. 
       www.menstuff.org/issues/byissue/breastcancer.html 
o National Cancer Institute. Male Breast Cancer Treatment PDQ  
       www.cancer.gov/cancertopics/pdq/treatment/malebreast/Patient  
       www.cancer.gov/cancertopics/pdq/treatment/malebreast/HealthProfessional  
2.6 CURRENT RESEARCH 
The European Organization for Research and Treatment of Cancer is coordinating a global 
effort, which joins forces from the Breast International Group and the North American Breast 
Cancer Groups, called International male Breast Cancer Program (Sousa 2013). This Program is 
composed of three parts: 1) retrospective joint analysis of all male breast cancer cases diagnosed 
in the last 20 years in the participating institutions, evaluating the biology of male breast cancer 
in detail with central pathology  review of tumor blocks and analysis of biological characteristics 
and promising biomarkers; 2) prospective international registry of all male breast cancer cases 
diagnosed in the participating institutions for a period of 2 years which is about to be launched 
and will provide valuable insight into the current treatment decisions as well as ensure that the 
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network in place can effectively recruit the needed patients for part 3 of the Program; 3) conduct 
of a prospective randomized trial (Sousa 2013).  
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3.0  METHODS  
3.1 PARTICIPANTS 
The target population for this study is genetic counselors who currently counsel cancer patients 
in the United States. Data on those counselors who work outside of the United States was also 
collected as this additional data might provide valuable information regarding ideas for future 
research.  The counselors must belong to either the Familial Cancer Risk Counseling special 
interest group of the National Society of Genetic Counselors (NSGC) or the general listserv of 
the NSGC (Appendix A).  The total amount of counselors who belong to the Familial Cancer 
Risk Counseling special interest group is 490.   It is unknown how many genetic counselors 
belong to the general listserv and not the special interest group.   As per the National Society of 
Genetic Counselors, the listserv is an electronic open forum discussion group only open to 
NSGC members and serves as one avenue of communication among members. It has been 
described by the NSGC organization as an electronic bulletin board i.e. one member can post a 
message for all other members to read and respond to if applicable. As per the NSGC, the 
listserv also helps to develop supportive professional relationships, address questions relevant to 
the genetic counseling community, and disseminate pertinent updates or changes in practice 
methods.  It was felt that members would be familiar with this approach for recruitment into a 
study as such recruiting practices have been used in the past.  
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3.2 PROTOCOL 
A review of literature regarding familial, genetic and psychosocial issues was done via PubMed.  
Genetic, familial and psychosocial issues were reviewed. The survey was conducted at the 
University of Pittsburgh. SurveyMonkey was responsible for collecting the data. After obtaining 
IRB approval from the University of Pittsburgh, an invitation to participate was sent in January 
2011 via a posting sent to the listserv of both the Familial Cancer Risk Counseling special 
interest group of the National Society of Genetic Counselors (NSGC) and the general listserv of 
the NSGC (Appendix A). To ensure confidentiality, the survey was encrypted during 
transmission to the target audience as well as their responses back to the Survey Monkey 
account. Also, the survey was distributed through a web collector that tracks respondents using 
cookies on their individual computers rather than a unique ID attached to the link. Subjects were 
evaluated with a 31 question survey utilizing both nominal and ordinal measurements (Appendix 
B). For ordinal measurements, the level of disagreement or agreement was measured via a 5 
level Likert scale defined as follows: 
o 1 - strongly disagree 
o 2 – disagree 
o 3 – neither agree nor disagree  
o 4 - agree 
o 5 – strongly agree 
Nominal measurements utilized yes/no or true false responses. The survey gathered information 
on such topics as the counselor’s experiences counseling men with breast cancer as well as their 
beliefs concerning the sociocultural, psychosocial, and familial issues impacting these men. 
Information on demographic variables concerning the respondent such as gender, years of 
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experience, work setting, number of cases per year and geographic area of practice was also 
gathered. The majority responded within one month. No reminders were sent to the counselors. 
Data collection ended in March 2011.  
3.3 DATA ANALYSIS 
Data analysis consisted of descriptive statistics displayed in graph form  This type of analysis 
will give us measure of central tendency of which   the mode will be most useful to fulfilling  the 
aims of the study. The percentages of each answer option will give us an idea of the range across 
the responses.  
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 Figure 32-Support Needed by Men versus Women in Disclosing Genetic Risk to Family 
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Figure 34-Diffenece in Counseling Men versus Women 
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Table 3-Additional Thoughts on Differences between Counseling Men and Women 
73 
Table 3 continued 
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For the discussion of the results from the questions utilizing the Likert scale, levels one 
and two will be combined to get the total percentage of those who agree, and levels 4 and 5 will 
be combined to get the percentage of those who disagree. Only the findings of the majority of 
counselors will be discussed.  
From the results of the questionnaire, the majority of counselors can be described as follows: 
92.5% are female, 49.3% have between 1-4 years experience, 78% are dedicated cancer 
counselors, 41.8% work in a University Medical Center and 98.5% see approximately 1-5 men in 
a year (Figure 1-4, Figure 8) 
In the work setting, none have posters in the physical environment that either depicts 
breast cancer as a male disease or as both a male or female disease (Figure 11, Figure 13). In 
fact, 74.2% do not have a pink ribbon displayed in the physical environment (Figure 12). The 
majority at 89.7% disagree with the statement that they try to schedule men with breast cancer on 
days where there will be a lot of male patients (Figure 21).  
The questionnaire results revealed that 82.3% of counselors believe that a breast cancer 
diagnosis is an equally traumatic event for both men and women (Figure 24). Yet, 73.8% do not 
agree that there are adequate support systems for men with breast cancer and 63.9% are not 
satisfied with the current state of research specifically related to the needs of men with breast 
cancer (Figure 28, Figure 29). Half of the counselors disagree with the statement that gender has 
no effect on a person’s willingness to discuss psychosocial issues and the majority at 56.5% 
chose level 3 in response to the statement that women with breast cancer can be an important 
source of support for men (Figure20, Figure 23). 
In a genetic counseling environment, 72.5% of counselors reports that the words breast 
cancer evoke thoughts of women (Figure 10).  Despite this, 58% do not agree that men would be 
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more comfortable with a male genetic counselor and 70.9% do not agree that they are more 
comfortable counseling women with breast cancer as compared to men (Figure 22, Figure 15). In 
fact, 77.5% agree that genetic counselors are an important source of psychosocial support for 
men with breast cancer (Figure 16). The vast majority of counselors at 96.8% report that men 
who attend counseling session are referred by their doctors and 65.6% believe men are in the 
acceptance stage at the time of the initial counseling session (Figure 9, Figure 25). The 
percentage of men diagnosed with breast cancer who choose BRCA testing is greater than the 
percentage of their female counterparts as reported by 53.2% of the counselors (Figure 6). An 
assessment of the psychosocial issues during a counseling session from the counselor’s 
perspective revealed the following: 51.6% disagree with the statement that more time is spent on 
genetic principles than with psychosocial issues, 69.4% agree that specific questions are asked 
regarding psychosocial issues, 58.1% believe men are just as willing to discuss psychosocial 
issues as their female counterparts and 57.4% believe men value information and psychosocial 
support equally (Figure 14, Figure17, Figure 19, Figure 27). 
During the process of risk discussion, 58.1% of counselors agree that men are more 
interested in discussing their family’s risk rather that personal risk (Figure 18).  Half of the 
counselors believe that men perceive themselves as primarily responsible for disclosure of 
genetic risk to family; alternately, the rest of the counselors believe that men rely on a close 
female relative for this task (Figure 31). For the disclosure process, 43.4% do not agree that men 
need more support in communicating genetic risk to family members (Figure 32). The majority 
of counselors at 53.3% chose level 3 in response to the question that men differ in the type of 
support needed in the counseling session (Figure 33). 
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During the counseling session, 60.7% of counselors did not feel there are adequate educational 
aids specifically related to men with breast cancer (Figure 26). Further, 58.3% believe that the 
current information regarding counseling men with breast cancer is extrapolated from research 
done on women with breast cancer (Figure 30). 
The length of the counseling session was reported by 71% to be equal in time for both 
men and women (Figure 7).  Counseling men is different than counseling women as reported by 
73% of counselors (Figure 34). The main differences reported are the following: focus on 
familial risk rather than personal risk, feeling of isolation and frustration with the lack of support 
and information available for men with breast cancer, and different medical management issues 
(Table 3). 
The majority of counselors at 43.3% reported that they believed the questionnaire is an 
effective tool for self-reflection (Figure 35). 
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5.0  DISCUSSION 
5.1  AIM 1 
The total number of respondents was 67(13.6%). As it is unknown how many genetic counselors 
belong to the general listserv and not the special interest group, this rate may not be entirely 
accurate.   The majority of cancer genetic counselors who responded to this survey are females 
with 1-5 year of experience who practice in a University Medical Center. The approximate 
number of men seen in a year ranges from 1 to 5 (Figures 1-4 and Figure 8). 
The counselors work in a physical environment that can be characterized as neutral in 
that there is not representation of cancer in terms of posters or symbols ( Figures 11- 13).None of 
the counselors try to schedule patients on days when male patients are present ( Figure 21). The 
gender of other patients does not appear to enter into the act of scheduling patients.  
The majority of counselors feel that a breast cancer diagnosis is equally traumatic for 
men and women (Figure 22).  This recognition validates the literature which reports men can 
experience feelings of shame and confusion and will even question their masculinity upon a 
diagnosis of breast cancer. Half of the counselors do not agree that gender has no effect on a 
person’s willingness to discuss psychosocial issues (Figure 20). This is surprising as this 
response seems to contradict the responses of the counselors to other questions and might be due 
to poor design of the question. For example, the majority of counselors believe that men value 
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informational and psychosocial support equally (Figure 27) and are just as willing to discuss 
psychosocial issues (Figure 19). Also, the counselors do not feel that more time is spent on 
genetic principles versus psychosocial issues (Figure 14). It is very encouraging to see such an 
emphasis on psychosocial issues and the positive responses of men to such issues during a 
session.  The finding in this survey that the majority of counselors are proactive in that they ask 
specific questions about psychosocial issues might explain such a response (Figure 17).  
Counselors agree that the words breast cancer evoke thoughts of women (Figure 10). This 
is understandable as the incidence of breast cancer is higher in women. A concern, based on the 
theory of projection countertransference, would be that these feelings could exacerbate the 
feelings of shame and confusion that men can experience with a disease considered to be 
gendered i.e. feminine.  It is unlikely that this would occur as counselors report that they are not 
more comfortable counseling women with breast cancer (Figure 15), nor do they feel that men 
would be more comfortable with a male genetic counselor (Figure 22).   In addition, counselors 
also recognize that counseling men with breast cancer is different from counseling women 
(Figure 34). 
Counselors feel they are an important source of psychosocial support for men.  This is 
extremely important as men value the support of health professional in the process of adjusting 
to their diagnosis. Counselors feel there is a lack of dedicated support systems for men with 
breast cancer (Figure 28) which makes the support of counselors crucial.  
Much of the research on men with breast cancer has been extrapolated from women most 
likely due to the small incidence of MBC which makes prospective studies highly impractical. 
The experiences of genetic counselors appear to support this finding. Counselors are not satisfied 
with the current state of research relating to the needs of men with breast cancer (Figure 29). 
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They feel there is a lack of educational aids dedicated to the needs of men (Figure 26). In 
general, the counselors feel that much of the information concerning the counseling of men is 
extrapolated from research done on women (Figure 30). 
Studies often report that men present in the denial stage regarding their diagnosis of 
breast cancer. Most counselors report that men are in the acceptance phase (Figure 25).  One of 
the reasons could be that men who choose genetic testing share common factors such as 
education level or cultural issues. A question assessing the demographics of men who choose 
genetic testing would have been informative. Also, some reports suggest that men need a period 
of concealment to adjust to the unique issues associated with a diagnosis of breast cancer.   This 
period of concealment, considered to be beneficial, can be misinterpreted as denial. 
Surprisingly, counselors feel that the number of men who choose BRCA testing is higher 
than the percentage of women.  The literature reports that fewer men than women chose genetic 
testing (Figure 6). A possible explanation could be that all men who present for counseling are 
qualified given that male breast cancer is a rare disease unlike female breast cancer.  In other 
words this high percentage may be due to the fact that more men qualify for genetic counseling 
rather than due to a man’s willingness to accept counseling which is what the question was 
intended to measure.  
As the literature reports, counselors feel men are more interested in discussing their 
family’s risk rather than their own personal cancer risk (Figure 18). Studies have reported that a 
close female relative takes on the role of disseminating risk information to the family. Half of the 
counselors find this to be true. The other half believes that men perceive themselves as 
responsible for disseminating risk in formation to their family. In an attempt to clarify the reason 
for this deviation from the literature, it would be interesting to compare demographics between 
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the men who are counseled by those who believe a close female relative discloses risk and those 
who believe that men disclose risk to detect any significant differences between the two groups 
or significant patterns within each group. 
5.2 AIM 2 
In general, counselors felt the survey was an effective tool for increasing self-awareness 
concerning their belief and valise about counseling men with breast cancer (Figure 35).  
5.3 LIMITATIONS 
There are biases that exist in this study that could affect the generalization of the results to the 
general population of men with breast cancer. In the design of the study, the category 3 on the 
Likert scale should have been defined in the recruiting letter. It is not possible to determine if the 
counselors who choose the level 3 agree a little, disagree a little or are not sure /have no opinions 
on the question which could be a valid interpretation. The majority of counselors chose level 3 in 
response to the statement that men differ in the type of support needed for disclosure of genetic 
information (Figure 33). They also chose level 3 in response to the statement that women with 
breast cancer can be an important source of support for men with breast cancer (Figure 23) and 
also in response to the statement that more support is needed for men in the process of 
communicating genetic risk to family members (Figure 32).  The findings for these three 
questions are difficult to determine  due to the vague definition of level 3 mentioned earlier. 
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The study population may not be representative of the target population which is all 
genetic counselors in the United States. Due to financial constraints obtaining a list of all genetic 
counselors in the United States was not possible.  Time constraints prevented the research 
needed to determine which of these counselors have experience in counseling those with a family 
or personal history of breast cancer. Recall bias could also exist. Because of the rare nature of the 
disease, it is conceivable that the lack of experience could affect a counselor’s interpretation of 
their experiences. Also, counselors may not adequately recall experiences if a long time has 
elapsed since counseling a man with breast cancer which is reasonable to consider as the average 
number of males seen in a year is 1-5. A desire to answer the questions in a way which reflects 
positive experiences for men may be another bias present in this study 
5.4 CONCLUSION 
Despite the lack of dedicated resources and research, the genetic counseling environment of men 
in the United States appears to be supportive of the needs these men face in their experience of 
breast cancer. Gender does not appear to affect the comfort level of the counselee or the 
counselor. This is important as the majority of counselors are female.  Counselors recognize that 
such a diagnosis is traumatic for men as it is for women. Counselors view themselves as an 
important source of support for these men. In fact, the assessment of psychosocial needs is just as 
much a part of the session as the assessment of informational needs. Men are more concerned 
about their family’s risk versus their own risk; however, they appear to pay a more active role in 
the dissemination of risk than what the literature suggests. This may be due to the proactive 
approach taken during the session in the assessment of psychosocial needs. 
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5.5 FUTURE RESEARCH 
Future research should focus on an assessment of the specific educational and psychosocial 
needs of men with breast cancer as well as their experiences as a patient in the medical 
community and as a member of society. Cooperative groups could be formed throughout not 
only the United States, but also other countries which would provide clues as to the effects of 
culture on the male experience. This could also be useful in the US as the population is culturally 
diverse. This information could provide counselors with the opportunity to better tailor a 
counseling session to meet the unique needs of men with breast cancer.  It is important to 
recognize the individuality of each male breast cancer patient. It is equally important to 
recognize that there are shared experiences that men with breast cancer experience in society.   
The challenge is to incorporate knowledge of these shared experiences with each man’s unique 
personality and life experience to devise a plan which will enable each man to make the best 













My name is Elizabeth Hight. I am a genetic counseling student at the University of 
Pittsburgh. I would like to extend to you an invitation to participate in a survey entitled A Survey 
of the Genetic Counseling Environment for Men Diagnosed with Breast Cancer which will serve 
as my thesis project. This is a descriptive survey designed to give information about the 
environment men with breast cancer experience in a genetic counseling session. The survey is 
being performed for research purposes. I have defined the environment as not only the physical 
setting of the session, but also the values and beliefs of genetic counselors concerning the 
sociocultural, psychosocial and familial influences that men with breast cancer experience in 
society. This survey has the potential to identify further areas of research as well as providing an 
opportunity for self-reflection concerning your experiences counseling men with breast cancer. It 
is 31 questions and will take approximately 30 minutes to complete.  
To participate, you must currently have experience counseling men with breast cancer. 
Although for the purposes of my thesis. I will be focusing on those responses from the United 
States, I would like to extend the invitation to those who participate outside of the United States 
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as this could provide valuable information for future research. The study is IRB approved, 
voluntary and the responses will be anonymous. There are no identifiable risks associated with 
this survey. If you have questions for the IRB, please contact them at irb@pitt.edu. If you have 
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